Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

Thorax

Volumn 53, Issue 10, 1998, Pages 835-841

  Nakamura, Yutaka ^a,c   Hoshino, Makoto ^a   Sim, Jae Joon ^a   Ishii, Koji ^a   Hosaka, Kimio ^a   Sakamoto, Teruo ^b  

^a TOHO UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Asthma; Leukotriene receptor antagonist; Pranlukast

Indexed keywords

ACETYLCHOLINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PRANLUKAST;

ADULT; ARTICLE; ASTHMA; BRONCHUS BIOPSY; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; GUINEA PIG; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SCORING SYSTEM;

EID: 0031750661     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.10.835     Document Type: Article

References (25)

1. Azzawi M, Bradley M, Jeffery PK. T lymphocytes and eosinophiles in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990;142:1407-13.
2. Darzen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci 1980;77:4354-8.
3. Dahlen SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
4. Hau XY, Dahlen SE, Lundberg JM, et al. Leukotrienes C4, D4 and E4 cause widespread and extensive plasma extravasation in the guinea pig. Naunyn Schmiedebergs Arch Pharmacol 1985;330:136-41.
5. Rinkema LE, Bemis KG, Fleisch JH. Production and antagonism of cutaneous vascular permeability in the guinea pig in reponse to histamame, leukotrienes and A23187. J Pharmacol Exp Ther 1984;230:550-7.
6. Marom Z, Shelhamer JH, Bach MK, et al. Slow-reacting substances of anaphylaxis, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
7. Wardlaw AJ, Hay H, Cromwell O, et al. Leukotrienes, LTC4 and B4 in bronchoalveolar lavage in bronchial asthma and respiratory diseases. J Allergy Clin Immunol 1989;84:19-26.
8. Lam S, Cham H, LeRiche JC, et al. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:1711-7.
9. Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge in acute asthma and in allergic rhinitis. Lancet 1989;i:584-8.
10. Okubo T, Takahashi H, Sumitano M, et al. Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol 1987;84: 149-55.
11. Ferreri NR, Howland WC, Stevenson DD, et al. Release of leukotrienes, prostaglandins and histamine into nasal secreation of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137:847-54.
12. Obata T, Okada Y, Motoishi M, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes isolated guinea pig tissues. Japan J Pharmacol 1992;60:227-37.
13. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
14. Takishima T, Hida W, Sasaki H, et al. Direct-writing recorder of the dose-response curves of the airway to methacholine. Chest 1981;80:600-6.
15. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
16. Snyder DW, Cho HL, Gilmore J. Endogenously formed leukotriene C4 activates LTC4 receptors in guinea pig trachea-strips. Eur J Pharmacol 1991;195:209-15.
17. Redkar-Brown DG, Aharony D. Inhibition of antigen-induced contraction of guinea pig trachea by ICI 198,615. Eur J Pharmacol 1989;165:113-21.
18. Nakagawa N, Obata T, Kobayashi T, et al. Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma. Eur J Pharmacol 1993;235: 211-9.
19. Spector SL, Smith LJ, Glass M, the Accolate Asthma Trialist Group. Effects of six weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-23.
20. Reiss TF, Altman LC, Chervinsky P, et al. Effect of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
21. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993;119:1059-66.
22. Fujimura M, Sakamoto S, Kamio Y, et al. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993;87:133-8.
23. Foster A, Chan CC. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig Int Arch Allergy Appl Immunol 1991;96:279.
24. Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;92:507-12.
25. Drazen JM. Comparative contractile responses to sulfido-peptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 1988;524:289-97.